Cargando…
The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report
INTRODUCTION: Calcitonin (Ct) and carcinoembrional antigen (CEA) are widely used as tumor markers for the post-operative follow-up of patients with medullary thyroid carcinoma (MTC). In patients with elevated serum Ct and CEA their dynamics can be described by calculating the doubling time (DT) - th...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2987862/ https://www.ncbi.nlm.nih.gov/pubmed/21047422 http://dx.doi.org/10.1186/1756-6614-3-10 |
_version_ | 1782192171624955904 |
---|---|
author | Gawlik, Tomasz d'Amico, Andrea Szpak-Ulczok, Sylwia Skoczylas, Aleksander Gubała, Elżbieta Chorąży, Anna Gorczewski, Kamil Włoch, Jan Jarząb, Barbara |
author_facet | Gawlik, Tomasz d'Amico, Andrea Szpak-Ulczok, Sylwia Skoczylas, Aleksander Gubała, Elżbieta Chorąży, Anna Gorczewski, Kamil Włoch, Jan Jarząb, Barbara |
author_sort | Gawlik, Tomasz |
collection | PubMed |
description | INTRODUCTION: Calcitonin (Ct) and carcinoembrional antigen (CEA) are widely used as tumor markers for the post-operative follow-up of patients with medullary thyroid carcinoma (MTC). In patients with elevated serum Ct and CEA their dynamics can be described by calculating the doubling time (DT) - the time, they need to double the serum concentration. Previous reports concluded that the Ct and CEA DT have prognostic value in MTC patients. PATIENTS AND METHODS: We retrospectively analyzed data of 70 MTC patients with elevated serum Ct or CEA. In total, doubling times were calculated and the DT of the less favorable marker was used to stratify the patients into the low- and high-risk group with the cut-off value of 2 years. The survival analysis was performed using Cox proportional hazard method. RESULTS: The doubling time < = 2 years of the less-favorable marker had significant prognostic impact for recurrence-free survival, HR = 2.61 (1.43-4.71) and overall survival, HR = 8.99 (3.51-23.04). CONCLUSIONS: The calcitonin and carcinembrional antigen doubling times of less than two years are negative prognostic factors for MTC recurrence-free and total survival in patients with persistent or recurrent disease. They may be used as predictive factors for more intensive search of disease localization in asymptomatic hypercalcitoninemia and for therapy choice in symptomatic disease. |
format | Text |
id | pubmed-2987862 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-29878622010-11-19 The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report Gawlik, Tomasz d'Amico, Andrea Szpak-Ulczok, Sylwia Skoczylas, Aleksander Gubała, Elżbieta Chorąży, Anna Gorczewski, Kamil Włoch, Jan Jarząb, Barbara Thyroid Res Research INTRODUCTION: Calcitonin (Ct) and carcinoembrional antigen (CEA) are widely used as tumor markers for the post-operative follow-up of patients with medullary thyroid carcinoma (MTC). In patients with elevated serum Ct and CEA their dynamics can be described by calculating the doubling time (DT) - the time, they need to double the serum concentration. Previous reports concluded that the Ct and CEA DT have prognostic value in MTC patients. PATIENTS AND METHODS: We retrospectively analyzed data of 70 MTC patients with elevated serum Ct or CEA. In total, doubling times were calculated and the DT of the less favorable marker was used to stratify the patients into the low- and high-risk group with the cut-off value of 2 years. The survival analysis was performed using Cox proportional hazard method. RESULTS: The doubling time < = 2 years of the less-favorable marker had significant prognostic impact for recurrence-free survival, HR = 2.61 (1.43-4.71) and overall survival, HR = 8.99 (3.51-23.04). CONCLUSIONS: The calcitonin and carcinembrional antigen doubling times of less than two years are negative prognostic factors for MTC recurrence-free and total survival in patients with persistent or recurrent disease. They may be used as predictive factors for more intensive search of disease localization in asymptomatic hypercalcitoninemia and for therapy choice in symptomatic disease. BioMed Central 2010-11-03 /pmc/articles/PMC2987862/ /pubmed/21047422 http://dx.doi.org/10.1186/1756-6614-3-10 Text en Copyright ©2010 Gawlik et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Gawlik, Tomasz d'Amico, Andrea Szpak-Ulczok, Sylwia Skoczylas, Aleksander Gubała, Elżbieta Chorąży, Anna Gorczewski, Kamil Włoch, Jan Jarząb, Barbara The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report |
title | The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report |
title_full | The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report |
title_fullStr | The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report |
title_full_unstemmed | The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report |
title_short | The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report |
title_sort | prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2987862/ https://www.ncbi.nlm.nih.gov/pubmed/21047422 http://dx.doi.org/10.1186/1756-6614-3-10 |
work_keys_str_mv | AT gawliktomasz theprognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport AT damicoandrea theprognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport AT szpakulczoksylwia theprognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport AT skoczylasaleksander theprognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport AT gubałaelzbieta theprognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport AT chorazyanna theprognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport AT gorczewskikamil theprognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport AT włochjan theprognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport AT jarzabbarbara theprognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport AT gawliktomasz prognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport AT damicoandrea prognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport AT szpakulczoksylwia prognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport AT skoczylasaleksander prognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport AT gubałaelzbieta prognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport AT chorazyanna prognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport AT gorczewskikamil prognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport AT włochjan prognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport AT jarzabbarbara prognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport |